

Technology Advisory Committee A Interests Register

Topic: Pembrolizumab in combination with platinum-based chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798] [ID3798]

Publication Date: 03/05/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Alexandra Taylor	Clinical expert	Direct & indirect-financial	Dr Taylor has worked on an MSD advisory board in February 2022. Dr Taylor also declared an indirect financial interest as they have received an education grant in an unrelated area, and a direct non-financial interest due to being a council member for the International Gynae Cancer Society (2020-present), council member and guidelines co-chair for the British Gynaecological Cancer Society.		21/03/2022 10/01/2023		It was agreed that these declarations would not prevent Dr Taylor from providing expert advice to the committee
Dr Susan Lalondrelle	Clinical expert	Indirect non-financial professional and personal	Dr Lalondrelle is conducting research on the use of pembrolizumab for other indications. Dr Lalondrelle also declared an indirect financial interest, as they have received educational and travel grants from MSD.		13/06/2022 10/01/2023		It was agreed that these declarations would not prevent Dr Lalondrelle from providing expert advice to the committee

Eluned Hughes	Patient expert	Indirect financial interest	Nominating organisation Jo's Cervical Cancer Trust has received educational grants from MSD. It was agreed that this declaration would not prevent them from providing expert advice to the committee.		30/05/2021 10/01/2023		It was agreed that this declaration would not prevent them from providing expert advice to the committee.
Becky Pennington	Committee member	Direct financial interest	She has received private consultancy fees from Roche for methodological research into carers' outcomes which is ongoing. This work is not specific to any drug or disease area and is not related to cervical cancer or bevacizumab.		09/12/2022		It was agreed that her declaration would not prevent Becky from participating in discussions on this appraisal.